Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
Aripiprazole
Borderline personality disorder
Systematic review (MeSH)
Journal
The Psychiatric quarterly
ISSN: 1573-6709
Titre abrégé: Psychiatr Q
Pays: United States
ID NLM: 0376465
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
27
07
2023
medline:
13
11
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive-compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.
Identifiants
pubmed: 37566261
doi: 10.1007/s11126-023-10045-8
pii: 10.1007/s11126-023-10045-8
doi:
Substances chimiques
Aripiprazole
82VFR53I78
Antipsychotic Agents
0
Olanzapine
N7U69T4SZR
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-557Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
The Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.
Ellison WD, Rosenstein LK, Morgan TA, Zimmerman M. Community and clinical epidemiology of borderline personality disorder. Psychiatr Clin North Am. 2018;41:561–73. https://doi.org/10.1016/j.psc.2018.07.008 .
doi: 10.1016/j.psc.2018.07.008
pubmed: 30447724
Instituto Nacional de Salud. Mental “Honorio Delgado – Hideyo Noguchi”. Nota de Prensa Nº 040 (“Honorio Delgado - Hideyo Noguchi” National Institute of Mental Health. Press Release No. 040). 2015. http://www.insm.gob.pe/oficinas/comunicaciones/notasdeprensa/2015/040.html . Accessed 01 Nov 2022.
National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder. https://www.nhmrc.gov.au/file/4896/download?token=jyKiMInW . Accessed 01 Nov 2022.
Paris J. Why patients with severe personality disorders are overmedicated. J Clin Psychiatry. 2015;76:e521. https://doi.org/10.4088/JCP.14com09441 .
doi: 10.4088/JCP.14com09441
pubmed: 25919846
Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512–8. https://doi.org/10.4088/JCP.14m09228 .
doi: 10.4088/JCP.14m09228
Barrachina J, Pascual JC, Ferrer M, Soler J, Rufat MJ, Andión O, et al. Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. Compr Psychiatry. 2011;52:725–30. https://doi.org/10.1016/j.comppsych.2010.11.009 .
doi: 10.1016/j.comppsych.2010.11.009
pubmed: 21349508
National Collaborating Centre for Mental Health. National Institute for Health and Care Excellence: Guidelines. British psychological society & royal college of psychiatrists. Borderline Personality Disorder: Treatment and Management. Leicester (UK): British Psychological Society (UK). 2009. https://pubmed.ncbi.nlm.nih.gov/21796831/ . Accessed 01 Nov 2022.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–66. https://doi.org/10.1016/s0149-2918(04)90066-5 .
doi: 10.1016/s0149-2918(04)90066-5
pubmed: 15220010
Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681–90. https://doi.org/10.1001/archpsyc.60.7.681 .
doi: 10.1001/archpsyc.60.7.681
pubmed: 12860772
Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(Supplement 1):S7-14. https://doi.org/10.1097/01.jcp.0000142282.62336.e9 .
doi: 10.1097/01.jcp.0000142282.62336.e9
pubmed: 15356415
Coustals N, Ménard ML, Cohen D. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. 2021;31:4–32. https://doi.org/10.1089/cap.2020.0014 .
doi: 10.1089/cap.2020.0014
pubmed: 32931315
Benabarre A, Campos JA, Russo F, Cerveri G, Prestia D, González S, et al. Tratamiento con aripiprazol en la práctica clínica: Consenso de un panel de expertos. Psiquiatr Biol. 2018;25:89–95. https://doi.org/10.1016/j.psiq.2018.11.002 .
doi: 10.1016/j.psiq.2018.11.002
Aguglia A, Serafini G, Nebbia J, Salvi V, Martinotti G, Corbo M, et al. Off-label use of second-generation antipsychotics in borderline personality disorder: A survey of Italian psychiatrists. J Pers Disord. 2021;35:321–35. https://doi.org/10.1521/pedi_2019_33_445 .
doi: 10.1521/pedi_2019_33_445
pubmed: 31609189
Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763–72. https://doi.org/10.1016/j.euroneuro.2015.03.017 .
doi: 10.1016/j.euroneuro.2015.03.017
pubmed: 25907249
The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0, updated Mar 2011. http://www.cochrane-handbook.org . Accessed 01 Nov 2022.
Cochrane methods bias. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials . Accessed 01 Nov 2022.
Sereda Y, Dembitskyi S. Validity assessment of the symptom checklist SCL-90-R and shortened versions for the general population in Ukraine. BMC Psychiatry. 2016;16:300. https://doi.org/10.1186/s12888-016-1014-3 .
doi: 10.1186/s12888-016-1014-3
pubmed: 27561313
pmcid: 5000449
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–96. https://doi.org/10.1111/j.2044-8260.1967.tb00530.x .
doi: 10.1111/j.2044-8260.1967.tb00530.x
pubmed: 6080235
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x .
doi: 10.1111/j.2044-8341.1959.tb00467.x
pubmed: 13638508
García-Batista ZE, Guerra-Peña K, Cano-Vindel A, Herrera-Martínez SX, Flores-Kanter PE, Medrano LA. Evidencias de validez y fiabilidad de las Puntuaciones del STAXI-2 para población general y hospitalaria: Estudio con una muestra de adultos de República Dominicana. Suma Psicol. 2018;25:21–9. https://doi.org/10.14349/sumapsi.2018.v25.n1.3 .
doi: 10.14349/sumapsi.2018.v25.n1.3
Lange A, Pahlich A, Sarucco M, Smits G, Dehghani B, Hanewald G. Psychometric characteristics and validity of the Dutch adaptation of the Buss-Durkee Hostility Inventory (the BDHI-D). Behav Res Ther. 1995;33:223–7. https://doi.org/10.1016/0005-7967(94)00043-J .
doi: 10.1016/0005-7967(94)00043-J
pubmed: 7887883
Lee MB, Lee YJ, Yen LL, Lin MH, Lue BH. Reliability and validity of using a Brief Psychiatric Symptom Rating Scale in clinical practice. J Formos Med Assoc. 1990;89:1081–7.
pubmed: 1982678
Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, Trauer T. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14:979–83. https://doi.org/10.1111/j.1365-2753.2007.00921.x .
doi: 10.1111/j.1365-2753.2007.00921.x
pubmed: 18462279
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil FP, Bachler E, et al. Aripiprazole in the treatment of patients with borderline placebo-controlled study. Am J Psychiatry. 2006;163:833–8. https://doi.org/10.1176/ajp.2006.163.5.833 .
doi: 10.1176/ajp.2006.163.5.833
pubmed: 16648324
Nickel MK, Loew TH, Pedrosa Gil FP. Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacol (Berl). 2007;191:1023–6. https://doi.org/10.1007/s00213-007-0740-0 .
doi: 10.1007/s00213-007-0740-0
Shafti SS, Kaviani H. Olanzapine vs aripiprazole in the management of borderline personality disorder. Curr Psychopharmacol. 2014. https://doi.org/10.2174/2211556003666140912223626 .
doi: 10.2174/2211556003666140912223626
Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. J Pers Disord. 2009;23:156–74. https://doi.org/10.1521/pedi.2009.23.2.156 .
doi: 10.1521/pedi.2009.23.2.156
pubmed: 19379093
Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4–12. https://doi.org/10.1192/bjp.bp.108.062984 .
doi: 10.1192/bjp.bp.108.062984
pubmed: 20044651
Bellino S, Rinaldi C, Bozzatello P, Bogetto F. Pharmacotherapy of borderline personality disorder: A systematic review for publication purpose. Curr Med Chem. 2011;18:3322–9. https://doi.org/10.2174/092986711796504682 .
doi: 10.2174/092986711796504682
pubmed: 21728970
Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;6:CD005653. https://doi.org/10.1002/14651858.CD005653.pub2 .
doi: 10.1002/14651858.CD005653.pub2
Turner BJ, Austin SB, Chapman AL. Treating nonsuicidal self-injury: A systematic review of psychological and pharmacological interventions. Can J Psychiatry. 2014;59:576–85. https://doi.org/10.1177/070674371405901103 .
doi: 10.1177/070674371405901103
pubmed: 25565473
pmcid: 4244876
Perez-Rodriguez MM, Bulbena-Cabré A, Bassir Nia A, Zipursky G, Goodman M, New AS. The neurobiology of borderline personality disorder. Psychiatr Clin North Am. 2018;41:633–50. https://doi.org/10.1016/j.psc.2018.07.012 .
doi: 10.1016/j.psc.2018.07.012
pubmed: 30447729
Dell’Osso B, Berlin HA, Serati M, Altamura AC. Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology. 2010;61:169–79. https://doi.org/10.1159/000297734 .
doi: 10.1159/000297734
pubmed: 20299811
Ruocco AC, Carcone D. A neurobiological model of borderline personality disorder: Systematic and integrative review. Harv Rev Psychiatry. 2016;24:311–29. https://doi.org/10.1097/HRP.0000000000000123 .
doi: 10.1097/HRP.0000000000000123
pubmed: 27603741
Joyce PR, Stephenson J, Kennedy M, Mulder RT, McHugh PC. The presence of both serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants increase the risk of borderline personality disorder. Front Genet. 2014;4:313. https://doi.org/10.3389/fgene.2013.00313 .
doi: 10.3389/fgene.2013.00313
pubmed: 24432029
pmcid: 3882668
Nemoda Z, Lyons-Ruth K, Szekely A, Bertha E, Faludi G, Sasvari-Szekely M. Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients. Behav Brain Funct. 2010;6:4. https://doi.org/10.1186/1744-9081-6-4 .
doi: 10.1186/1744-9081-6-4
pubmed: 20205808
pmcid: 2823641
Soria-Chacartegui P, Villapalos-García G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. https://doi.org/10.3389/fphar.2021.711940 .
doi: 10.3389/fphar.2021.711940
pubmed: 34335273
pmcid: 8316766